TRYAL Company Profile

Background

TRYAL, founded in February 2023 and headquartered in Austin, Texas, is an eClinical software platform company dedicated to revolutionizing the clinical trials landscape. The company's mission is to simplify and accelerate clinical research processes by integrating advanced technologies, including artificial intelligence (AI), into user-friendly tools that enhance productivity without adding complexity. TRYAL's vision is to empower clinical trial teams to manage studies more efficiently, ensuring high-quality data collection and streamlined workflows. The company holds significant industry importance by addressing the persistent challenges that slow down clinical trials and overwhelm study teams.

Key Strategic Focus

TRYAL's strategic focus centers on automating and simplifying the configuration and deployment of eClinical solutions. The company specializes in developing AI-powered platforms that transform clinical study protocols into operational software solutions and critical documents within minutes. Key technologies utilized include the TRYAL Accelerator, an AI-enabled platform that configures common clinical study solutions directly from the protocol, and a suite of eClinical tools such as eConsent, eCOA (electronic Clinical Outcome Assessment), Home Healthcare, and Video Anonymization services. TRYAL primarily targets the biopharmaceutical industry, contract research organizations (CROs), and clinical trial teams seeking to enhance efficiency and data quality in their studies.

Financials and Funding

In February 2023, TRYAL announced its launch with over $6 million in seed funding. The funding is intended to support the company's rapid scaling and the development of its innovative eClinical solutions. Specific details regarding notable investors and the utilization of the capital have not been publicly disclosed.

Pipeline Development

TRYAL's product development pipeline includes several key solutions:

eConsent Module: Launched in May 2023, this module automates and simplifies the informed consent process, enhancing participant comprehension and improving site compliance with real-time visibility.

Video Anonymization Service: Introduced in April 2024, this service ensures participant privacy by anonymizing video data collected during clinical trials, allowing for secure and compliant data sharing.

TRYAL Accelerator: An AI-powered platform that configures eClinical solutions directly from the clinical protocol, significantly reducing study startup times and enhancing transparency.

These solutions are at various stages of development and deployment, with ongoing enhancements to meet the evolving needs of clinical trial teams.

Technological Platform and Innovation

TRYAL distinguishes itself through its proprietary technologies and innovative approaches:

TRYAL Accelerator: This AI-enabled platform analyzes clinical study protocols and automates the configuration of essential systems and documents needed to run a clinical study, transforming protocols into operational solutions within minutes.

eCOA Solution: A comprehensive suite designed for efficient and accurate patient data collection, supporting various modalities such as ePRO (electronic Patient-Reported Outcomes), ClinRO (Clinician-Reported Outcomes), ObsRO (Observer-Reported Outcomes), and PerfRO (Performance Outcomes).

Video Anonymization Service: Utilizing advanced algorithms, this service anonymizes video data to protect participant privacy while preserving valuable clinical information, facilitating the use of video-based assessments in trials.

These technologies leverage AI and automation to streamline clinical trial processes, reduce manual errors, and enhance data quality.

Leadership Team

TRYAL's leadership comprises seasoned professionals with extensive experience in the eClinical and technology sectors:

Shae Wilkins, Chief Executive Officer: A recognized innovator in clinical research technology with over 22 years of entrepreneurial leadership. Shae has built and scaled successful eClinical technology companies, including Altavoz (acquired by IQVIA) and Arrowhead Electronic Healthcare (acquired by Bracket).

Evan Mallory, Chief Technology Officer: An experienced technical founder with more than 20 years of engineering leadership across various industries, including healthcare, finance, and consumer SaaS applications. Evan has built high-performance solutions and led agile teams across multiple countries.

Amanda Nite, Senior Vice President of Product & Operations: Bringing over 20 years of clinical and technical operations experience, Amanda has held leadership positions at Oracle, Medidata, BioClinica (now Clario), and ICON plc, driving advancements in clinical technology and managing high-performing teams.

As of June 2025, there have been no significant changes or appointments within the company's leadership team.

Competitor Profile

Market Insights and Dynamics

The eClinical solutions market is experiencing significant growth, driven by the increasing complexity of clinical trials and the need for efficient data management. The market is characterized by rapid technological advancements, with AI and automation playing pivotal roles in enhancing trial efficiency and data quality.

Competitor Analysis

Key competitors in the eClinical solutions space include:

Medidata Solutions: Offers a comprehensive cloud-based platform for clinical trials, including eConsent and eCOA solutions.

Veeva Systems: Provides cloud-based software for the global life sciences industry, including clinical data management and eClinical solutions.

Clario (formerly BioClinica): Specializes in endpoint data solutions, including eCOA and imaging services for clinical trials.

These competitors focus on delivering integrated platforms that streamline clinical trial processes, with varying degrees of AI integration and automation capabilities.

Strategic Collaborations and Partnerships

As of June 2025, specific details regarding TRYAL's strategic collaborations and partnerships have not been publicly disclosed. The company continues to focus on developing and enhancing its proprietary technologies to strengthen its market position and innovation capacity.

Operational Insights

TRYAL's strategic considerations in relation to major competitors include:

Market Position: By offering AI-powered solutions that automate and simplify clinical trial processes, TRYAL positions itself as a disruptive innovator in the eClinical space.

Competitive Advantages: The company's ability to rapidly transform clinical protocols into operational solutions, coupled with a user-centric design approach, differentiates it from competitors relying on more traditional, manual processes.

Strategic Opportunities and Future Directions

TRYAL's strategic roadmap includes:

Expansion of AI Capabilities: Continuing to enhance the TRYAL Accelerator and other AI-driven tools to further reduce study startup times and improve data quality.

Product Diversification: Developing additional eClinical solutions to address emerging needs in the clinical trial industry, such as remote monitoring and decentralized trial management.

Market Penetration: Strengthening relationships with biopharmaceutical companies and CROs to expand the adoption of TRYAL's solutions across various therapeutic areas and trial phases.

By leveraging its current strengths in AI and automation, TRYAL is well-positioned to capitalize on these opportunities and drive future growth in the eClinical solutions market.